BIM mediates synergistic killing of B-cell acute lymphoblastic leukemia cells by BCL-2 and MEK inhibitors

por Korfi, K, Smith, M, Swan, J, Somervaille, T C P, Dhomen, N, Marais, R
Publicado 2016

Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients

por Valpione, S., Gremel, G., Mundra, P., Middlehurst, P., Galvani, E., Girotti, M.R., Lee, R.J., Garner, G., Dhomen, N., Lorigan, P.C., Marais, R.
Publicado 2018

Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma

por Lee, R J, Gremel, G, Marshall, A, Myers, K A, Fisher, N, Dunn, J A, Dhomen, N, Corrie, P G, Middleton, M R, Lorigan, P, Marais, R
Publicado 2018

Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA

por Gremel, G., Lee, R. J., Girotti, M. R., Mandal, A. K., Valpione, S., Garner, G., Ayub, M., Wood, S., Rothwell, D. G., Fusi, A., Wallace, A., Brady, G., Dive, C., Dhomen, N., Lorigan, P., Marais, R.
Publicado 2016

The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers

por Saturno, G., Lopes, F., Niculescu-Duvaz, I., Niculescu-Duvaz, D., Zambon, A., Davies, L., Johnson, L., Preece, N., Lee, R., Viros, A., Holovanchuk, D., Pedersen, M., McLeary, R., Lorigan, P., Dhomen, N., Fisher, C., Banerji, U., Dean, E., Krebs, M.G., Gore, M., Larkin, J., Marais, R., Springer, C.
Publicado 2021